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nos. MG808405–MG808410). BLAST (https://blast.ncbi.
nlm.nih.gov/Blast.cgi) and phylogenetic analyses of the 
segment 2 sequences showed that the EHDV recently iso-
lated in cattle in Israel belongs to serotype 1 and is closely 
related to the IbAr22619 strain from Nigeria, with which it 
shares 95.72%–95.76% identity (Figure).
Retrospective analysis of clinical signs in EHDV-1–
infected cattle enabled us to conclude that in many farms 
EHDV infection was asymptomatic or subclinical; milk-
yield reduction, fever, and recumbency were the only prom-
inent clinical signs observed during the outbreak. However, 
animals with BTV and EHDV co-infections showed more 
severe clinical signs, including fever, abortion, lameness, 
subcutaneous emphysema, and death.
During recent years, several new arboviruses have 
been detected in Israel that were not identified previous-
ly. BTV serotype 3 was first identified in 2016 but prob-
ably was present in Israel since at least 2013 (9), EHDV 
serotype 6 was identified in 2015 (6), EHDV serotype 1 
was found in 2016, and Shuni virus was detected in 2014 
(10). These findings showed that new introductions of ar-
thropodborne viral infections into the Middle East region 
had occurred. Molecular epidemiologic data indicate the 
viruses originated in Africa, as ours and other studies (5,6) 
have shown. Molecular diagnostics, vector-control strate-
gies, and epidemiologic studies should be implemented in 
Israel to mitigate potential risk for future outbreaks.
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A unique outbreak of Ross River virus (RRV) infection was 
reported in Fiji in 1979. In 2013, RRV seroprevalence among 
residents was 46.5% (362/778). Of the residents who were 
seronegative in 2013 and retested in 2015, 10.9% (21/192) 
had seroconverted to RRV, suggesting ongoing endemic 
circulation of RRV in Fiji.
Ross River virus (RRV) is an Alphavirus of the family Togaviridae and is transmitted to humans by Aedes 
and Culex mosquitoes (1). Marsupials are considered im-
portant reservoirs of RRV (1). Clinical manifestations of 
RRV infections include fever, rash, and arthralgia. RRV 
is endemic to Australia, where it causes ≈5,000 cases of 
epidemic polyarthritis annually (1). Outbreaks of RRV 
infection were reported during 1979–1980 in Fiji, the 
Cook Islands, American Samoa, New Caledonia, and 
Wallis and Futuna (1–3). Subsequently, RRV infections 
were detected in travelers returning from Fiji during 
1997–2009 (3) and in patients with suspected dengue in 
Fiji in 2005 (4).
The Republic of the Fiji Islands comprises 322 islands 
distributed among 4 administrative divisions (Central, 
Western, Eastern, and Northern) and has a population of 
≈830,000. Apart from RRV, the 4 serotypes of dengue virus 
were the only mosquitoborne viruses known to circulate in 
Fiji until the recent emergence of Zika and chikungunya vi-
ruses (5). We report evidence of endemic RRV circulation 
in Fiji on the basis of serologic analysis of blood samples 
collected in 2013 and 2015.
Our study included 778 participants recruited during 
September–November 2013 from the Central, Western, 
and Northern divisions for a community-based serosurvey 
for leptospirosis and typhoid (6). Among the residents from 
the Central division who had participated in the 2013 sur-
vey, 333 had blood drawn again during October–Novem-
ber 2015, including 311 whose serum sample collected in 
2013 was available for testing. We tested all blood samples 
for RRV IgG by using a recombinant antigen-based micro-
sphere immunoassay (7). We analyzed the data with Graph-
Pad Prism 6.03 using the Fisher or χ2 test. We considered p 
values <0.05 to be significant. 
The prevalence of RRV antibodies among partici-
pants in 2013 was 46.5% and was lower in the Central 
(38.1%) than the Western (58.6%; p<0.0001) and North-
ern (55.9%; p = 0.0108) divisions (Table). The prevalence 
of RRV antibodies among the participants sampled in the 
Central division in 2015 (37.2%) was similar to results 
from this division in 2013 (38.1%). In 2013, a total of 
37.4% of the participants born after 1982 (postoutbreak) 
had RRV antibodies, and this rate in 2015 (26.9%) was 
not significantly different (p = 0.0685). The prevalence of 
RRV antibodies increased with age (p<0.0001 in 2013, p 
= 0.0020 in 2015) and was higher in rural than in urban 
(p<0.0001 in 2013, p = 0.0197 in 2015) and periurban 
areas (p = 0.0060 in 2013). No difference by sex was ob-
served. Among the 311 participants with available serum 
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Table. Prevalence of Ross River virus antibodies in a representative subset of the population of Fiji sampled during September–
November 2013 (n = 778) and October–November 2015 (n = 333)* 
Variable 
No. seropositive/mo. tested (% [95% CI]) 
2013 2015 
Birth year   
 <1982 197/336 (58.6 [53.4–63.9]) 68/144 (47.2 [39.6–55.7]) 
 >1982 165/441 (37.4 [32.9–42.1]) 56/189 (29.6 [23.2–36.7]) 
  1982–1990 58/117 (49.6 [41.1–58.9]) 17/38 (44.7 [31.4–61.4) 
  1991–2000 66/146 (45.2 [37.7–53.6]) 20/66 (30.3 [21.3–42.9]) 
  2001–2010 40/170 (23.5 [18.1–30.7]) 19/83 (22.9 [15.8–33.5]) 
  >2011 1/8 (12.5 [0.3–52.7]) 0/2 (0.0 [0.0–84.2]) 
Sex   
 F 195/423 (46.1 [41.5–51.0]) 73/190 (38.4 [32.1–45.8]) 
 M 167/354 (47.5 [42.2–52.5]) 51/143 (35.7 [28.6–44.1]) 
Division   
 Central 172/451 (38.1 [33.9–42.8]) 124/333 (37.2 [32.4–42.7]) 
 Northern 33/59 (55.9 [44.1–68.7]) ND 
 Western 157/268 (58.6 [52.8–64.5]) ND 
Zone   
 Rural 189/344 (54.9 [49.8–60.3]) 52/113 (46.0 [37.5–55.6]) 
 Periurban 55/135 (40.7 [33.2–49.5]) 27/77 (35.1 [26.0–46.8]) 
 Urban 117/298 (39.3 [34.1–45.1]) 45/143 (31.5 [24.8–39.8]) 
Total 362/778† (46.5 [43.1–50.1]) 124/333 (37.2 [32.4–42.7]) 
*ND, no data (participants were not recruited from the Northern and Western divisions in 2015). 
†For 1 participant, information about age and sex were not available; for another participant, information about the zone of residence was not available. 
 
samples collected in both 2013 and 2015, a total of 21 
(10.9%) of the 192 participants who had no detectable 
RRV antibodies in 2013 had seroconverted to RRV by 
2015 (data not shown).
A serosurvey conducted after the RRV outbreak 
in Fiji in 1979 detected RRV antibodies in 92% of the 
participants from the Western division (2). In our study, 
which was conducted in 2013, RRV antibody prevalence 
in the Western, Central, and Northern divisions ranged 
from 38.1% to 58.6%, and 37.4% of persons born after 
1982 had RRV antibodies, suggesting that RRV circulated 
in all 3 divisions after the 1979 outbreak. The report of 
RRV infection in travelers or inhabitants from Fiji during 
1997–2009 (3,4), the observations that 10.9% of the sero-
negative participants in our study seroconverted to RRV 
during 2013–2015, and the increase in the prevalence of 
RRV antibodies with age, strongly suggest endemic RRV 
transmission in Fiji.
The finding that RRV seroprevalence was higher in 
rural than in urban and periurban environments suggests 
increased transmission risks in the rural areas, potential-
ly because of higher-risk occupations of rural residents 
(including farming and outdoor work), greater exposure 
related to rural housing or other environmental factors, 
greater animal reservoir density, the possibility that non-
domestic mosquito species in Fiji such as Aedes vigilax, 
Ae. polynesiensis, Ae. pseudoscutellaris, Ae. albopictus, 
and Culex annulirostris might be more competent vec-
tors of RRV than peridomestic mosquito species such as 
Ae. aegypti (8).
Serosurveys conducted in American Samoa in 2010 
(1), in French Polynesia during 2011–2013 (9) and 2014–
2015 (7), and our study in Fiji during 2013–2015 suggest 
that endemic circulation of RRV in the Pacific region con-
tinued, or recommenced, after 1979–1980. These data pro-
vide further evidence for endemic transmission of RRV in 
areas where marsupials are absent (10). Because of exten-
sive travel between Australia and the Pacific Islands, it is 
plausible that RRV is repeatedly seeded into the Pacific 
region. Whether this plays an important role in perpetuat-
ing local transmission in the Pacific Islands is unknown. As 
previously illustrated with Zika and chikungunya viruses, 
a risk exists for emerging arboviruses to be imported from 
the Pacific to other parts of the world, and RRV could be 
the next unexpected threat.
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We report a case of malignant otitis externa with jugular 
vein thrombosis caused by Aspergillus flavus. Magnetic 
resonance imaging revealed an unusual ink smudge pat-
tern deep in a cervical abscess. The pattern was consistent 
with mycetoma and may be important for diagnosing these 
life-threatening infections.
A 73-year-old male patient sought care from the oto-rhinolaryngology department at University Hospital, 
Marseille, France. He had a 5-month history of malig-
nant otitis externa (MOE), which was worsening despite 
4 months of treatment with intravenous ceftazidime, oral 
ciprofloxacin, and topical neomycin, polymyxin B, dexa-
methasone, and thiomersal combination. The patient had a 
history of high blood pressure, treated with perindopril and 
nicardipine, and diabetes mellitus, inadequately controlled 
(hemoglobin A1c 7.7%) with metformin and sitagliptin.
The patient was admitted, and otoscopic examination 
found otorrhea, inflammation, and stenosis of the right 
external auditory canal; we could not see the tympanic 
membrane. Examination of the cranial nerve was normal. 
Pure-tone audiogram showed a right mixed hearing loss 
with air-bone gap at 15 dB and symmetric bone curve by 
presbycusis. Laboratory testing showed elevated erythro-
cyte sedimentation level (42 mm at 1 h, 82 mm at 2 h) and 
leukocytosis (11 g/L); C-reactive protein results were with-
in reference range. A computed tomography (CT) scan of 
the head showed thickening of the ear skin; focal tympanal 
bone osteolysis; partial right mastoid air cells and middle-
ear cavity opacification; and osteolysis of the occipital, sty-
loid, and mastoid bones consistent with MOE (Appendix 
Figure, https://wwwnc.cdc.gov/EID/article/25/4/18-0710-
App1.pdf). Magnetic resonance imaging (MRI) with con-
trast media confirmed skull base osteomyelitis, evidenced 
by bone lysis and marrow enhancement of the clivus (Fig-
ure, panels A–C). Both MRI and CT showed a right jugular 
vein thrombosis and cellulitis and abscess in the carotid and 
perivertebral spaces. Abscess content had an unusual as-
pect: T2-weighted imaging signal void foci surrounded by 
a hypersignal rim.
We treated the right jugular vein thrombosis with 
enoxaparin. The patient underwent surgical debridement 
with facial nerve monitoring; we collected transmastoid 
biopsy samples and pus for microbiological analysis and 
inserted a transtympanic aerator. Direct microscopic ex-
amination of the samples showed hyaline septate hyphae 
consistent with hyalohyphomycosis. Biopsy samples grew 
2 bacteria, Corynebacterium striatum and Enterococcus 
faecalis, and 1 filamentous fungus, Aspergillus flavus, that 
we identified by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (Microflex LT, https://
www.bruker.com) against an in-house database described 
by Normand et al. (1). Etest antifungal susceptibility test-
ing (bioMérieux, https://www.biomerieux.com) showed 
that the A. flavus strain was sensitive to voriconazole 
(MIC 0.380 mg/L) and resistant to amphotericin B (MIC 
12 mg/L). We stopped administration of auricular drops, 
continued intravenous ceftazidime (1.5 g/d) and oral cip-
rofloxacin (1.5 g/d), and started voriconazole therapy (6 
mg/kg/12 h intravenously, followed by 400 mg/d orally). 
Otalgia, otorrhea, and inflammatory external auditory canal 
symptoms were relieved, and the patient recovered after 6 
weeks. No further follow-up was available.
Fungi cause ≈10% of MOE (2). The 3 leading species, 
by decreasing frequency, are A. fumigatus, A. flavus, and 
A. niger (3). A. flavus is more frequently involved in MOE 
than is A. niger (3,4).
Jugular vein thrombosis (JVT) was previously reported 
in MOE (5) and other conditions such as Lemierre syndrome, 
invasive fungal infection, or any inflammatory process in-
cluding otitis media. Various pathogens can cause JVT, es-
pecially Fusobacterium necrophorum and zygomycetes. 
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